“We are extremely proud to receive this award, after a pivotal year of accelerated growth of our portfolio and our organization”, expressed Thierry Abribat, Ph.D., founder and CEO of Amolyt Pharma. Indeed, the young start-up is building on an already strong pipeline with three products (one in phase 3, one in phase 1 and one in pre-clinical development). “In 4 years, we’ve built up this mature portfolio from scratch”, says the entrepreneur.
The European Lifestars Awards (ELA) Biotech Company of the Year is awarded to a life sciences company that has excelled in strategy, process, goals and execution, and has created value for patients, investors, employees and society at large.
The biotech’s most advanced product, eneboparatide, targets patients with hypoparathyroidism. This rare disease is characterized by a deficiency in parathyroid hormone (PTH), a hormone that regulates calcium levels in the blood. It affects around 110,000 patients in Europe and 80,000 patients in the USA, 80% of whom are women (half of whom are postmenopausal and likely to develop osteoporosis). 26% of patients suffer from chronic kidney disease or renal failure.
Eneboparatide is a synthetic peptide that mimics the natural hormone, an agonist of the parathyroid hormone receptor 1 (PTHR1). It aims to normalize blood calcium to symptoms and urinary calcium excretion to prevent renal complications, while maintaining renal complications, and maintaining bone
integrity (without increasing bone loss in postmenopausal women in particular).
The molecule has passed clinical phases 1 and 2. The Phase 2 trial included 28 patients with hypoparathyroidism. In particular, the results demonstrated normalization of blood calcium levels, a remarkable effect on urinary calcium excretion in patients most at risk, with no negative impact on bone. Results from the ongoing phase 3 trial in 165 patients (USA, Canada Canada, Europe, UK) are expected in the first half of 2025.
“With neboparatide, based on a distinct mechanism of action and Phase 2 results, we believe we have the only product capable of addressing all the clinical needs of patients with hypoparathyroidism. This is what we intend to do in Phase 3 study. This major milestone, if positive, will enable us to continue
to grow our company by integrating commercialization activities in order to make this product available to patients worldwide“, says Thierry Abribat.
Amolyt’s second molecule, AZP-3813, is a growth hormone receptor antagonist for the potential treatment of acromegaly. This condition can cause exaggerated growth of the face and extremities, and even very large stature (gigantism) when it occurs before puberty. It is accompanied by numerous symptoms, including joint pain, and medical complications such as diabetes or heart disease. This
product is currently in phase 1.
The biotech has finally acquired AZP-40XX, in the pre-clinical phase. This family of monoclonal antibodies monoclonal antibodies target the parathyroid hormone receptor (PTHR1), with the ultimate aim of targeting symptoms and complications of primary hyperparathyroidism (excessive secretion of parathyroid hormone leading to hypercalcemia) and humoral hypercalcemia of malignant origin (often caused by cancer).
Based in the suburbs of Lyon and in Boston (USA), the startup can count on a panel of investors, from whom it has raised a total of 212 million euros, in three rounds, since its launch in 2019 (Novo Holding ; EQT Life Science ; Andera Partners ; Kurma Partners ; Sofinnova Partners, Intermediate Capital Group (ICG),
Innobio2 by Bpifrance, MGB Venture ; Pontifax, Orbimed ; Sectoral Asset Management ; Tekla ; CTI Life Science ,…)
